Loading...
XNAS
NUWE
Market cap76mUSD
Jul 16, Last price  
15.95USD
1D
131.16%
1Q
1,606.80%
IPO
-100.00%
Name

Nuwellis Inc

Chart & Performance

D1W1MN
P/E
—
P/S
8.72
EPS
—
Div Yield, %
—
Shrs. gr., 5y
339.33%
Rev. gr., 5y
9.66%
Revenues
9m
-1.40%
381,7611,253,1212,731,740422,040108,302400,0250059,000295,00059,0001,289,0003,553,0004,998,0005,511,0007,441,0007,921,0008,543,0008,864,0008,740,000
Net income
-11m
L-47.43%
000000-16,196,000-14,065,000-21,758,000-25,587,000-26,583,000-15,792,000-13,382,000-17,032,000-18,114,000-15,836,000-19,578,000-14,525,000-20,209,000-10,624,000
CFO
-10m
L-46.53%
000000-13,089,000-13,083,000-17,362,000-22,644,000-22,989,000-16,292,000-11,920,000-14,560,000-16,367,000-16,572,000-17,880,000-15,149,000-17,937,000-9,591,000
Earnings
Aug 11, 2025

Profile

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
URL
https://www.nuwellis.com/
IPO date
Feb 16, 2012
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,740
-1.40%
8,864
3.76%
8,543
7.85%
Cost of revenue
6,273
9,303
8,130
Unusual Expense (Income)
NOPBT
2,467
(439)
413
NOPBT Margin
28.23%
4.83%
Operating Taxes
5
8
9
Tax Rate
0.20%
2.18%
NOPAT
2,462
(447)
404
Net income
(10,624)
-47.43%
(20,209)
39.13%
(14,525)
-25.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,927
2,109
9,449
BB yield
Debt
Debt current
238
432
224
Long-term debt
852
1,304
1,744
Deferred revenue
Other long-term liabilities
468
2,843
6,868
Net debt
(4,005)
(2,064)
(16,338)
Cash flow
Cash from operating activities
(9,591)
(17,937)
(15,149)
CAPEX
(60)
(149)
(122)
Cash from investing activities
(60)
330
14,728
Cash from financing activities
10,962
3,683
9,423
FCF
3,145
(1,674)
1,598
Balance
Cash
5,095
3,800
18,306
Long term investments
Excess cash
4,658
3,357
17,879
Stockholders' equity
(298,836)
(287,435)
(260,511)
Invested Capital
306,379
294,465
280,720
ROIC
0.82%
0.14%
ROCE
32.71%
2.04%
EV
Common stock shares outstanding
1,327
56
174
Price
Market cap
EV
EBITDA
2,777
(77)
785
EV/EBITDA
Interest
5,607
3,483
9,247
Interest/NOPBT
227.28%
2,238.98%